Ultromics Limited articles

Ultromics will be sharing its groundbreaking AI research and innovation at the American Society of Echocardiography’s annual Scientific Sessions.

ASE’s Foundations and the Future of Cardiovascular Ultrasound sessions bring together echo professionals and enthusiasts from across forty-five countries with a selection of networking events, seminars, and workshops from the top minds in echocardiography. 

Ultromics, a pioneer in usin

Preliminary results of a large-scale study demonstrating the clinical benefits of EchoGo® Heart Failure were shared at the American College of Cardiology (ACC 2023) conference last month.

Using only an apical four-chamber ultrasound view, this new AI-enabled platform can identify heart failure with preserved ejection fraction (HFpEF) and has been shown to minimize the indeterminate classification of HFpEF in both undefined and well-defined cohorts. [1]

In this post,

Heart failure with preserved ejection fraction (HFpEF) is a multifactorial and multisystemic disorder that represents more than 50% of all heart failure cases.[1]

Epidemiologic data from the Framingham Study, an international cohort study, shows a rapid increase in the prevalence of HFpEF over the past three decades, from 41% to 56% and, conversely, a decrease in the prevalence of HFrEF from 44% to 31%. [2]

Because of its complex pathophysiology

Heart failure affects about 6.2 million Americans and is rising in prevalence. With half of these cases presenting as heart failure with preserved ejection fraction (HFpEF), it’s essential for both the medical community and the population at large to have a better understanding of its pathology. [1,2]

Knowing the differences between HFpEF and its counterpart, heart failure with reduced ejection fraction (HFrEF), including contrasts in their cellular and molecular presentations,

Heart failure with preserved ejection fraction (HFpEF) is currently affecting over half of heart failure patients. 

The Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS), two departments within the U.S. Federal Government’s Department of Health and Human Services (DHHS), use the International Classification of Diseases (ICD) for coding and reporting. Data retrieved through ICD provides critical knowledge on the ex

Heart failure with preserved ejection fraction (HFpEF) has recently been recognized as the single greatest unmet need in cardiovascular medicine, overtaking heart failure with reduced ejection fraction (HFrEF) and becoming the most common form of heart failure, with a prevalence that is increasing by 1% annually.^[1] Despite this, there remains no gold standard in diagnosing HFpEF. 

Diagnosing HFpEF is not as straightforward when com

Overview 

What is HFpEF?

Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome in which patients have signs and symptoms of HF as the result of high left ventricular (LV) filling pressure, despite normal or near-normal LV ejection fraction (EF).

Most patients with HFpEF also display normal LV volumes and an abnormal diastolic filling pattern (i.e, diastolic dysfunction). HFpEF occurs when the muscl

Recent clinical trials investigating sodium-glucose cotransporter 2 inhibitors (SGLT2i) have highlighted that this drug is highly effective in treating patients with heart failure with preserved ejection fraction (HFpEF).

HFpEF is a complex disease which accounts for more than half of all heart failure (HF) hospital admissions and is an increasing disease burden. ^[1] The prevalence of HFpEF is climbing, reflecting an increasingly elderly